Added to YB: 2026-08-25
Pitch date: 2026-08-20
MRNA [neutral]
Moderna, Inc.
+4.34%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$57.9B
Pitch Price
$133.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
-24.82
P/E
-18.12
EV/Sales
23.48
Sector
Biotechnology
Category
growth
Show full summary:
Moderna's Cancer Vaccine Just Read Out. You Only Get Half of It.
MRNA (overview): mRNA-4157 individualized cancer vaccine (w/ Merck) posted late-stage data, stock soared. But Moderna owns only half—costs/profits split 50/50 w/Merck. Bull: manufacturing moat, validated method. Bear: eroding base biz, likely equity raise into strength, unmapped reimbursement, needs 2nd tumor type (lung) to work. Hold small.
Read full article (5 min)